Report Detail

Medical Devices & Consumables Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update

  • RnM2733856
  • |
  • 07 January, 2019
  • |
  • Global
  • |
  • 31 Pages
  • |
  • GlobalData
  • |
  • Medical Devices & Consumables

Summary

Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents 2

      List of Tables 3

        List of Figures 3

          Guardant Health Inc Company Overview 4

            Guardant Health Inc Company Snapshot 4

              Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4

                Guardant Health Inc – Pipeline Analysis Overview 7

                  Guardant Health Inc - Key Facts 7

                    Guardant Health Inc - Major Products and Services 8

                      Guardant Health Inc Pipeline Products by Development Stage 9

                        Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

                          Guardant Health Inc Pipeline Products Overview 13

                            Anti-RSP03 Antibody Based Blood Test 13

                              Anti-RSP03 Antibody Based Blood Test Product Overview 13

                                Gene-Based Test - Lung Cancer 14

                                  Gene-Based Test - Lung Cancer Product Overview 14

                                    GUARDANT360 15

                                      GUARDANT360 Product Overview 15

                                        GUARDANT360 Clinical Trial 16

                                          Guardant360 CDx Test - Tepotinib 18

                                            Guardant360 CDx Test - Tepotinib Product Overview 18

                                              Guardant360 Companion Diagnostic Assay - Glesatinib 19

                                                Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview 19

                                                  Guardant Health Inc - Key Competitors 20

                                                    Guardant Health Inc - Key Employees 21

                                                      Guardant Health Inc - Locations And Subsidiaries 22

                                                        Head Office 22

                                                          Recent Developments 23

                                                            Guardant Health Inc, Recent Developments 23

                                                              Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients 23

                                                                Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit 23

                                                                  Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications 23

                                                                    Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer 24

                                                                      May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications 24

                                                                        Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison 25

                                                                          Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay 25

                                                                            Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients 26

                                                                              Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood 26

                                                                                Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial 27

                                                                                  Appendix 28

                                                                                    Methodology 28

                                                                                      About GlobalData 31

                                                                                        Contact Us 31

                                                                                          Disclaimer 31

                                                                                          Summary:
                                                                                          Get latest Market Research Reports on Guardant Health Inc (GH) . Industry analysis & Market Report on Guardant Health Inc (GH) is a syndicated market report, published as Guardant Health Inc (GH) - Product Pipeline Analysis, 2018 Update. It is complete Research Study and Industry Analysis of Guardant Health Inc (GH) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                          Last updated on

                                                                                          REPORT YOU MIGHT BE INTERESTED

                                                                                          Purchase this Report

                                                                                          $750.00
                                                                                          $1,500.00
                                                                                          $2,250.00
                                                                                          597.75
                                                                                          1,195.50
                                                                                          1,793.25
                                                                                          696.75
                                                                                          1,393.50
                                                                                          2,090.25
                                                                                          114,922.50
                                                                                          229,845.00
                                                                                          344,767.50
                                                                                          62,580.00
                                                                                          125,160.00
                                                                                          187,740.00
                                                                                          Credit card Logo

                                                                                          Related Reports


                                                                                          Reason to Buy

                                                                                          Request for Sample of this report